



## Vertex NZ Statement – 1 April 2021

Vertex was pleased to participate in the meeting organised by Cystic Fibrosis New Zealand yesterday. The discussions were helpful and provided us further insight from the various stakeholders who attended the meeting.

During the meeting, Vertex confirmed that we are actively working on our dossiers for submission to Medsafe and PHARMAC. We intend to request a priority review from Medsafe for this application which should shorten the review process.

The process of registration and funding of medicines in New Zealand is complex and takes time and is a shared goal for multiple stakeholders in the healthcare system. We recognize the frustrations of those that are still waiting and while there are set processes that must be followed, we remain committed to working with PHARMAC in creative and innovative ways for people living with CF to access our treatments in New Zealand.

###

### **Media contact:**

Rachael Bylykbashi

Communications Director

Vertex (Australia and New Zealand)

mobile: +61 427 872 380

email: [rachael\\_bylykbashi@vrtx.com](mailto:rachael_bylykbashi@vrtx.com)

### **About Vertex**

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.